About US
Contact us
-
Faltering drug development poses risk to future revenuesWith so many drugs falling off the patent cliff, and taking drugmakers' revenues down with them, there has been a penchant to bet on riskier new drugs with bigger potential payoffs. But a new report f2012/9/11
-
FDA gives generic drugs 'super' statusWith generic drugmakers now slated to kick in a significant piece of the FDA's outside funding, the agency appears ready to give them the position they have earned. According to a letter from Janet W2012/9/11
-
Drug shortages ease but remain serious problemPatients who can't get the drugs they need because they're in short supply will not be impressed by the news, but the problem ofdrug shortageshas so far been less severe this year than last. Through2012/9/10
-
Pfizer settles another generic run at Detrol LAPfizer ($PFE) has locked in another agreement to stave off generic competition toDetrol LA, its drug for people with overactive bladders.Reuterssays Pfizer and Mylan ($MYL) have reached an agreement o2012/9/10
-
New Indian price caps would raise another hurdle to Big PharmaHere's another chapter for the growing treatise known as Emerging Markets Are Tougher Than We Thought, by Big Pharma. India's newly proposed price controls would put another damper on drugmakers, ex2012/9/7
-
Novartis chief to employees: We need a quality rebootIt has been a tough year for Novartis CEO Joseph Jimenez. In the course of 9 months, the company ($NVS) received a three-plant FDA warning letter, closed its key OTC plant and had to tell shareholders2012/9/7
-
Roche expects to keep Rituxan monopoly until 2015You know the patent-cliff drill: Companies can count down the days until their biggest drugs lose exclusivity--and they do. Not so for biologic treatments, even now that FDA has a pathway for biosim2012/9/7
-
JAMA says FDA jumped the gun on Gilenya, PradaxaThe FDA's balancing act is no easy feat. In fact, it just might be impossible. As soon as the agency gets congressional direction to revamp and speed up approvals, experts in other quarters conclu2012/9/6
-
Roche displays the fruits of $9B in R&D spendingIf Roche ($RHHBY) had a drug-development trading card, its stats would look something like this: R&D budget of $9 billion, with 72 development programs, 19 late-stage studies and 12 candidates f2012/9/6
-
Sanofi plans to buy back $152M in Genzyme CVRsSanofi ($SNY) plans to buy back up to $152 million in contingent value rights linked to last year's buyout of Genzyme. The French drugmaker says it would purchase about 30% of the CVRs, which pay of2012/9/5